- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01658904
Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma
Phase I / II Study Of Carfilzomib (CFZ) Intensification Early After Autologous Transplantation (AHCT) For Plasma Cell Myeloma
Background:
- Plasma cell myeloma is a type of cancer that affects the plasma cells in the bone marrow. It can be difficult to treat with chemotherapy. One possible treatment combines chemotherapy with a stem cell transplant. To make this treatment more effective, researchers want to give another drug along with the transplant. This drug, carfilzomib, is often used to help treat plasma cell myeloma. However, it is not usually given along with the transplant. Researchers want to see if it is safe and effective to combine the stem cell transplant with carfilzomib, and if it improves the results of the transplant.
Objectives:
- To test the safety and effectiveness of carfilzomib given with stem cell transplant for plasma cell myeloma.
Eligibility:
- Individuals between 18 and 75 years of age who are having a stem cell transplant to treat plasma cell myeloma.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies and a bone marrow biopsy will also be performed.
- Participants will have their own stem cells collected for the transplant. The transplant will be performed according to the standard of care.
- All participants will receive carfilzomib on the first 2 days after transplant. The study doctors will determine the number of additional doses that they may have.
- Treatment will be monitored with frequent blood tests and imaging studies.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background:
- Despite very significant progress in therapy for plasma cell myeloma (PCM) in the last decade, the disease remains mostly incurable.
- High-dose chemotherapy followed by autologous hematopoietic cell transplantation (AHCT) continues to be a critical component of early treatment for PCM, but it is clear that the disease is not eradicated by the present high-dose therapy strategy, while intensifying the preparative regimen has, to this day, resulted in either no improvement in disease control or increased toxicity.
- Carfilzomib (CFZ) is a newer proteasome inhibitor with increased activity and a safer toxicity profile than bortezomib in PCM. The favorable toxicity profile makes it a likely candidate for increasing anti-PCM drug exposure in the early post-AHCT period.
Objectives:
Primary Objectives
-Evaluate feasibility and toxicity of an increasing number of doses of CFZ administered in the early period post-AHCT for PCM
Secondary Objective
- Evaluate the immune reconstitution post-AHCT following CFZ therapy
- Evaluate the effects of the addition of CFZ in the early post-AHCT period on the response rate at day 100 post-AHCT
Eligibility:
- Newly diagnosed subjects with PCM following induction therapy
- Subjects with documentation of persistent/refractory disease who have received no more than 2 salvage regimens following relapse and who have not undergone AHCT
- Adequate organ functions with no major co-morbidity
- Age greater than 18 years and less than or equal to 75 years
Design:
- Phase I/II study on the backbone of high-dose melphalan on day -2 pre-AHCT
- Addition of an increasing number of doses of CFZ in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects:
Cohort 1: add CFZ 20 mg/m^2 on days +1, +2
Cohort 2 : add CFZ 20 mg/m^2 on days: +1, +2, +8, +9
Cohort 3: add CFZ 20 mg/m^2 on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following
engraftment: CFZ 20 mg/m^2 given on days 42-43 then CFZ 56 mg/m^2 given on days 49-50, 56-57, then on days 70-71, 77-78 and 84-85
-Dose-limiting toxicity, incidence of engraftment failure and treatment-related mortality are the objects of early stopping rules for safety purposes
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center, 9000 Rockville Pike
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- INCLUSION CRITERIA:
Multiple myeloma criteria for newly or recently diagnosed subjects
- Presence of clonal plasma cells in the bone marrow greater than or equal to 10% or a documented clonal plasmacytoma (either by immuno-histochemistry or by Ig gene rearrangement), AND
- Presence of an M-component; an M-component (immunoglobulin G (IgG) or immunoglobulin A (IgA)) in serum greater than or equal to 1g/dl or in urine greater or equal to 200 mg/24 h.
ALTERNATIVELY, if the M-component criterion is not met:
- An abnormal serum free light chain (FLC) ratio on the serum FLC assay, or if the FLC ratio is normal,
- Baseline bone marrow must have 10% or greater clonal plasma cells
AND, IN ADDITION, presence of one or more of the following attributable to the disease (in the presence or absence of an M-component):
- Calcium elevation greater than 11.5 mg/dl (2.65 mmol/l)
- Renal insufficiency: serum creatinine greater than 2 mg/dl (177 mmol/l) or less than 60ml/min.
- Hemoglobin less than 10 g/dl (12.5 mmol/l) or 2 g/dl (1.25 mmol/l) below lower normal
- Bone disease (lytic lesions or osteopenia)
- Other evidence of disease activity: repeated infections, secondary amyloidosis, hyperviscosity, hypogammablobulinemia
Criteria for subjects with persistent or recurrent disease
Subjects with recurrent or persistent disease are eligible if:
- Criteria for initiating therapy for plasma cell myeloma (PCM) had been present at the time of initiation of therapy or there is clear clinical indication for salvage therapy.
- They have not undergone an autologous transplant for the treatment of PCM
- They have received no more than two salvage regimens for the treatment of recurrent or persistent PCM (each regimen may include more than one cycle)
Other eligibility criteria
-Age > 18 years and less than or equal to 75 years.
In subjects between 65 and 75 years of age, physiologic age and co-morbidity will be thoroughly evaluated before enrolling. Specifically, any history of cardiovascular pathology or symptoms not clearly fitting the exclusion criteria of Section 2.1.2 will prompt an evaluation by a Clinical Center Cardiologist and eligibility will be considered on a case-by-case basis.
- Karnofsky performance status of 70% or greater (Eastern Cooperative Oncology Group (ECOG) 0 or 1)
- Ejection fraction (EF) by multi-gated acquisition scan (MUGA) or 2-D echocardiogram within institution normal limits. In case of low ejection fraction (EF), the subject may remain eligible after a stress echocardiogram is performed if the EF is more than 35% and if the increase in EF with stress is estimated at 10% or more.
- creatinine clearance > 25ml/min (measured on a 24 hour urine collection)
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x upper limit of normal
- Bilirubin less than or equal to1.5 (except if due to Gilbert's disease)
- Corrected carbon dioxide diffusing capacity (DLCO) greater than or equal to 40% on pulmonary function tests
EXCLUSION CRITERIA:
- Prior allogeneic or autologous stem cell transplantation
- Prior treatment with Carfilzomib (CFZ) is not an exclusion
- History of recent (< 6 months) cerebrovascular accident
- History of documented recent (< 6 months) pulmonary embolus
- Clinically significant cardiac pathology:
- Myocardial infarction within 6 months prior to enrollment,
- Class III or IV heart failure according to New York Heart Association (NYHA),
- Uncontrolled angina,
- Severe uncontrolled ventricular arrhythmias, or
- Electrocardiographic evidence of acute ischemia or active conduction abnormalities felt to pose a significant cardiac riks by a Cardiology consultant
- Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis.
- Human immunodeficiency virus (HIV) seropositive
- Acute active infection requiring treatment (systemic antibiotics, antivirals, or antifungals) within 14 days prior to enrollment
- Active hepatitis B or C infection
- Uncontrolled hypertension or uncontrolled diabetes within 14 days prior to enrollment
- Major surgery within 21 days prior to enrollment
- Non-hematologic malignancy within the past 3 years with the exception of a) adequately treated basal cell carcinoma, squamous cell skin cancer, or thyroid cancer; b) carcinoma in situ of the cervix or breast; c) prostate cancer of Gleason Grade 6 or less with stable prostate-specific antigen levels; or d) cancer considered cured by surgical resection or unlikely to impact survival during the duration of the study, such as localized transitional cell carcinoma of the bladder or benign tumors of the adrenal or pancreas
- Significant neuropathy (Grades 3 4, or Grade 2 with pain) within 14 days prior to randomization
- Known history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ)
- Patients known or found to be pregnant
- Female patients of childbearing age who are unwilling to practice contraception
- Patients may be excluded at the discretion of the principal investigator (PI) if it is deemed that allowing participation would represent an unacceptable medical or psychiatric risk.
- Patients must be able to give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort 1- CFZ 20 mg/m^2 (Day 1,2)
Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT) •Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects: Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2 Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70. |
|
Experimental: Cohort 2- CFZ 20 mg/m^2 (Day 1,2,8,9)
Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT) •Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects: Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2 Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70. |
|
Experimental: Cohort 3-CFZ 20 mg/m^2 (Day1,2,8,9/AHCT)
Phase I/II study on the backbone of high-dose melphalan on day -2 pre-autologous hematopoietic cell transplantation (AHCT) •Addition of an increasing number of doses of Carfilzomib (CFZ) in the early post-AHCT period introduced in a step-wise fashion in 3 successive cohorts of 3 to 15 subjects: Cohort 1: add CFZ 20 mg/m^2 intravenous (IV) on days +1, +2 Cohort 2 : add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 Cohort 3: add CFZ 20 mg/m^2 IV on days: +1, +2, +8, +9 and add an early post-AHCT consolidation following engraftment: CFZ 20 mg/m^2 IV given on days 42-43 then CFZ 56 mg/m^2 IV given on days 49-50, 56-57, then on days 70. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Engraftment Failure Transplant Related Mortality
Time Frame: up to day 100
|
Engraftment failure is defined as the failure to achieve neutrophil engraftment by day 21; defined from day 0, day of autologous hematopoietic cell transplantation (AHCT), as the first of three consecutive days on which the patient's absolute neutrophil count is greater than 0.5x10(9)/l following the nadir.
Transplant related mortality is defined as any subject who dies in the first 100 days post-AHCT of any non-relapse related cause.
|
up to day 100
|
Number of Participants With Adverse Events
Time Frame: 8 months and 15 days
|
Here is the number of participants with adverse events.
For a detailed list of adverse events, see the adverse event module.
|
8 months and 15 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Evaluate the Immune Reconstitution Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Following Carfilzomib (CFZ) Therapy
Time Frame: Post-AHCT following CFZ therapy
|
Post-AHCT following CFZ therapy
|
Evaluate the Effects of the Addition of Carfilzomib (CFZ) in the Early Post-Pre-autologous Hematopoietic Cell Transplantation (AHCT) Period on the Response Rate at Day 100 Post-AHCT
Time Frame: Day 100 post-AHCT
|
Day 100 post-AHCT
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
- Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, Perrone G, Pastorelli F, Tura S, Baccarani M, Cavo M. Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005 Mar;74(3):212-6. doi: 10.1111/j.1600-0609.2004.00382.x.
- Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR; Eastern Cooperative Oncology Group. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006 Jan 20;24(3):431-6. doi: 10.1200/JCO.2005.03.0221. Epub 2005 Dec 19.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Leukemia
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia, Plasma Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Melphalan
Other Study ID Numbers
- 120179
- 12-C-0179
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Myeloma
-
Lawson Health Research InstituteThe Ottawa Hospital; Hamilton Health Sciences Corporation; Dalhousie University; Niagara Health SystemActive, not recruitingMultiple Myeloma in Relapse | Multiple Myeloma With Failed Remission | Multiple Myeloma Stage I | Multiple Myeloma Progression | Multiple Myeloma Stage II | Multiple Myeloma Stage IIICanada
-
National Cancer Institute (NCI)Active, not recruitingSmoldering Multiple Myeloma | Refractory Multiple Myeloma | DS Stage I Multiple Myeloma | DS Stage II Multiple Myeloma | DS Stage III Multiple MyelomaUnited States
-
Fred Hutchinson Cancer Research Center/University...National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Mayo ClinicCompletedMultiple Myeloma | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
National Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
City of Hope Medical CenterCompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
University of WashingtonNational Cancer Institute (NCI)TerminatedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedStage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Refractory Multiple MyelomaUnited States
Clinical Trials on Filgrastim
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CompletedNon-Hodgkin's Lymphoma | Plasma Cell MyelomaUnited States
-
Franziska WachterHarvard Clinical and Translational Science Center (Harvard Catalyst)RecruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | MDS | Aml | Myeloid Neoplasm | Myeloid Malignancies | Inherited Bone Marrow Failure SyndromeUnited States
-
National Cancer Institute (NCI)CompletedRhabdomyosarcoma | Synovial Sarcoma | Ewing's Sarcoma | MPNST | High-risk SarcomaUnited States
-
Trio FertilityRecruitingPrimary Ovarian Insufficiency | Premature Ovarian FailureCanada
-
Ottawa Hospital Research InstituteCompletedEarly Stage Breast CancerCanada
-
Eurofarma Laboratorios S.A.CompletedNeutropenia in Breast CancerBrazil
-
Medical University of BialystokUnknownIncrease Muscle Strength in Patients With Muscular DystrophyPoland
-
PfizerCompletedHealthy VolunteersUnited States
-
Seoul St. Mary's HospitalUnknownLeukemia, Myeloid, AcuteKorea, Republic of
-
Andrews Research & Education FoundationFloridaRecruiting